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HAL-treated patients that had responded to therapy at
each of the three thresholds defined. Six-week response-
curves were compared using log-rank tests.
RESULTS: As the threshold for classifying a patient as a
responder increased, the relative divergence between
drug-response curves increased with the OLZ treatment
group consistently attaining higher proportions of re-
sponders than the HAL treatment group. At a minimal
threshold for response (20%), 77% of OLZ versus
70% of HAL-treated patients responded by week 6 (p 
0.002). At a high bar threshold for response (65%),
25.9% of OLZ versus 15.6% of HAL-treated patients re-
sponded by week 6 (p  .001). Furthermore, a separation
of response rates in favor of OLZ could be seen as early
as week 2.
CONCLUSION: Rigorously as compared to minimally de-
fined thresholds for response clearly differentiate the greater
likelihood of patients achieving superior improvement on
the novel antipsychotic OLZ as compared to HAL.
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OBJECTIVE: The objective of this analysis was to ex-
plore the association of improvement in QoL and depres-
sive symptoms with robust acute treatment response of
olanzapine (OLZ) versus haloperidol (HAL).
METHODS: Data was analyzed post-hoc from a double-
blind, randomized (OLZ versus HAL), trial of 1996 pa-
tients with schizophrenia or a related disorder. The treat-
ment response was classified into four groups based on
improvement of the Brief Psychiatric Rating Scale (BPRS)
total scores at 6 weeks: 20%, 20–40%, 40–65% and
65% improvement. Mean percent changes of Quality
of Life Scale (QLS) scores and Montgomery-Asberg De-
pression Rating Scale (MADRS) were determined.
RESULTS: There was a significant positive association
between the more robust level of response (i.e., 65%)
and improvements in depressive symptoms and QLS
across treatment groups. Patients treated with OLZ
started to access moderate improvement (10% im-
provement) in QLS once they attained a 20% or greater
improvement in BPRS while for the HAL-treated pa-
tients, only those who had a 65% or greater response in
BPRS could exceed moderate QLS improvement. The
mean percent change in QLS in the 20–40% BPRS re-
sponse group was 13.4% for OLZ versus 1% for HAL (p 
0.031) and in the 65% or greater BPRS response group
was 41.8% for OLZ versus 32.8% for HAL (p  0.45).
Similar observations were demonstrated in improvement
on the MADRS. For patients with a 40–65% BPRS re-
sponse, the improvement in MADRS was 34.9% for
OLZ versus 6.7% for HAL (p  0.027).
CONCLUSION: A more robust categorical acute treat-
ment response resulted in greater improvement in QoL
and depressive symptoms across treatment groups. For pa-
tients attaining the same level of acute treatment response
though, there may be significantly greater improvements in
QoL and depressive symptoms enjoyed by OLZ-treated
patients compared to those treated with HAL.
PMH3
PATIENT MEDICATION ATTITUDE AFTER 
SWITCHING TO ZIPRASIDONE FROM OTHER 
ANTIPSYCHOTICS
Dugar A1, Awad G2, Voruganti LNP2
1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 
2University of Toronto, Toronto, ON, Canada
OBJECTIVE: Patients with schizophrenia switched from
conventional antipsychotics, olanzapine, or risperidone,
to ziprasidone show significant improvements in weight,
prolactin levels, and lipid profile. Since such benefits may
affect patient behavior and resource use, Drug Attitude
Inventory (DAI) was administered to assess attitudes/feel-
ings about antipsychotic therapy.
METHODS: Three six-week multi-center, open-label,
parallel-group trials of similar design were undertaken in
stable schizophrenic outpatients switched from conven-
tional antipsychotics (n  108), olanzapine (n  104), or
risperidone (n  58) because of poor tolerability or insuf-
ficient efficacy. Each trial randomized patients to 1 of 3
switch strategies—“slow” taper, “fast” taper, or “abrupt
discontinuation” of prior medication before initiating
ziprasidone (80 mg/day for 2 days; 40–160 mg/day there-
after). The 10-question true/false DAI was administered
at baseline and week six. The primary summary measure
was total score (sum of responses to all questions). Data
were combined from all switch subsets for each study be-
cause there was no significant difference in mean change
from baseline to week six among strategies. Positive total
score indicated likely compliance, whereas negative total
score, likely noncompliance. A categorical linear model
was used to analyze marginal probabilities of favorable
responses over total, attitudinal, and subjective question
sets.
RESULTS: Total DAI scores improved significantly in
patients switched to ziprasidone from conventionals (P 
.003) or risperidone (P  .008). Categorical analysis
identified significant improvements in patients switched
to ziprasidone from conventionals (P  .05 all items, P 
.02 subjective) and a trend toward improved scores in
those switched from olanzapine (P  .06 for both). DAI
improvement from baseline to week six was consistently
driven by positive change in subjective feelings. Ziprasi-
done was safe, well-tolerated, and effective, regardless of
dose or switch strategy.
